Vertex Pharmaceuticals (VRTX) Short Interest Ratio & Short Volume

Short interest is the volume of Vertex Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of January 31st, traders have sold 4,560,000 shares of VRTX short. 1.78% of Vertex Pharmaceuticals' shares are currently sold short. Learn More on Vertex Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRTX shares currently have a short interest ratio of 3.0. Learn More on Vertex Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Vertex Pharmaceuticals: Arrowpoint Investment Partners Singapore Pte. Ltd., Wolverine Trading LLC, Squarepoint Ops LLC, Torno Capital LLC, Sig Brokerage LP, Point72 Asset Management L.P., Nomura Holdings Inc., Millennium Management LLC, LMR Partners LLP, Group One Trading LLC, Eisler Capital Management Ltd., Cresset Asset Management LLC, Cubist Systematic Strategies LLC, Citadel Advisors LLC, Cantor Fitzgerald L. P., Capstone Investment Advisors LLC, Bank of America Corp DE, BNP Paribas Financial Markets, Jane Street Group LLC, Lido Advisors LLC, Tudor Investment Corp ET AL, Boothbay Fund Management LLC, Parallax Volatility Advisers L.P., Two Sigma Securities LLC, Susquehanna International Group LLP, Hsbc Holdings PLC, Concourse Financial Group Securities Inc., PEAK6 LLC, Walleye Trading LLC, Walleye Capital LLC, Barclays PLC, Capital Fund Management S.A., Capula Management Ltd, JPMorgan Chase & Co., Simplex Trading LLC, Twin Tree Management LP, HighTower Advisors LLC, Allianz Asset Management GmbH, Wolverine Asset Management LLC, Valeo Financial Advisors LLC, IMC Chicago LLC, Fiduciary Family Office LLC, and JPMorgan Chase & Co.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.78% of Vertex Pharmaceuticals' floating shares are currently sold short.

Vertex Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 4,560,000 shares, an increase of 3.9% from the previous total of 4,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Vertex Pharmaceuticals currently has issued a total of 256,790,000 shares. Some of Vertex Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vertex Pharmaceuticals currently has a public float of 256,190,000 shares.

1.78% of Vertex Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Vertex Pharmaceuticals: Amgen Inc. (2.38%), Gilead Sciences, Inc. (1.85%), Regeneron Pharmaceuticals, Inc. (2.00%), Alnylam Pharmaceuticals, Inc. (2.27%), Biogen Inc. (2.59%), United Therapeutics Co. (4.59%), Incyte Co. (3.06%), BioMarin Pharmaceutical Inc. (2.36%), Neurocrine Biosciences, Inc. (2.41%), Exelixis, Inc. (4.72%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks.

Short selling VRTX is an investing strategy that aims to generate trading profit from Vertex Pharmaceuticals as its price is falling. VRTX shares are trading up $3.91 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Vertex Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VRTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRTX, twice per month. The most recent reporting period available is January, 31 2025.